File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment

TitleTumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment
Authors
KeywordsDrug resistance
Non-cell-autonomous drug resistance
Tumor
Tumor microenvironment
Issue Date2019
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.molecular-cancer.com
Citation
Molecular Cancer, 2019, v. 18, article no. 69, p. 1-16 How to Cite?
AbstractDrug resistance is of great concern in cancer treatment because most effective drugs are limited by the development of resistance following some periods of therapeutic administration. The tumor microenvironment (TME), which includes various types of cells and extracellular components, mediates tumor progression and affects treatment efficacy. TME-mediated drug resistance is associated with tumor cells and their pericellular matrix. Noninherent-adaptive drug resistance refers to a non-cell-autonomous mechanism in which the resistance lies in the treatment process rather than genetic or epigenetic changes, and this mechanism is closely related to the TME. A new concept is therefore proposed in which tumor cell resistance to targeted therapy may be due to non-cell-autonomous mechanisms. However, knowledge of non-cell-autonomous mechanisms of resistance to different treatments is not comprehensive. In this review, we outlined TME factors and molecular events involved in the regulation of non-cell-autonomous resistance of cancer, summarized how the TME contributes to non-cell-autonomous drug resistance in different types of antineoplastic treatment, and discussed the novel strategies to investigate and overcome the non-cell-autonomous mechanism of cancer non-cell-autonomous resistance.
Persistent Identifierhttp://hdl.handle.net/10722/269524
ISSN
2023 Impact Factor: 27.7
2023 SCImago Journal Rankings: 8.222
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorQu, Y-
dc.contributor.authorDou, B-
dc.contributor.authorTan, HYH-
dc.contributor.authorFeng, Y-
dc.contributor.authorWang, N-
dc.contributor.authorWang, D-
dc.date.accessioned2019-04-24T08:09:29Z-
dc.date.available2019-04-24T08:09:29Z-
dc.date.issued2019-
dc.identifier.citationMolecular Cancer, 2019, v. 18, article no. 69, p. 1-16-
dc.identifier.issn1476-4598-
dc.identifier.urihttp://hdl.handle.net/10722/269524-
dc.description.abstractDrug resistance is of great concern in cancer treatment because most effective drugs are limited by the development of resistance following some periods of therapeutic administration. The tumor microenvironment (TME), which includes various types of cells and extracellular components, mediates tumor progression and affects treatment efficacy. TME-mediated drug resistance is associated with tumor cells and their pericellular matrix. Noninherent-adaptive drug resistance refers to a non-cell-autonomous mechanism in which the resistance lies in the treatment process rather than genetic or epigenetic changes, and this mechanism is closely related to the TME. A new concept is therefore proposed in which tumor cell resistance to targeted therapy may be due to non-cell-autonomous mechanisms. However, knowledge of non-cell-autonomous mechanisms of resistance to different treatments is not comprehensive. In this review, we outlined TME factors and molecular events involved in the regulation of non-cell-autonomous resistance of cancer, summarized how the TME contributes to non-cell-autonomous drug resistance in different types of antineoplastic treatment, and discussed the novel strategies to investigate and overcome the non-cell-autonomous mechanism of cancer non-cell-autonomous resistance.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.molecular-cancer.com-
dc.relation.ispartofMolecular Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectDrug resistance-
dc.subjectNon-cell-autonomous drug resistance-
dc.subjectTumor-
dc.subjectTumor microenvironment-
dc.titleTumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment-
dc.typeArticle-
dc.identifier.emailTan, HYH: hyhtan@hku.hk-
dc.identifier.emailFeng, Y: yfeng@hku.hk-
dc.identifier.emailWang, N: ckwang@hku.hk-
dc.identifier.authorityFeng, Y=rp00466-
dc.identifier.authorityWang, N=rp02075-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12943-019-0992-4-
dc.identifier.pmid30927928-
dc.identifier.pmcidPMC6441162-
dc.identifier.scopuseid_2-s2.0-85063719345-
dc.identifier.hkuros297580-
dc.identifier.volume18-
dc.identifier.spagearticle no. 69, p. 1-
dc.identifier.epagearticle no. 69, p. 16-
dc.identifier.isiWOS:000462941900023-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1476-4598-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats